Angizaar/Angizaar-H

Angizaar/Angizaar-H Special Precautions

losartan + hydrochlorothiazide

losartan

Manufacturer:

Micro Labs

Distributor:

Zizawa Healthcare
Full Prescribing Info
Special Precautions
General: Losartan should not be used with potassium-sparing diuretics. Serum potassium should be monitored in elderly patients and in patients with renal impairment.
In patients who are volume-depleted, hypotension may occur on initiation of therapy. In such patients, the condition should be corrected and a lower starting dose of losartan is recommended. Changes in renal function have been reported in susceptible patients treated with losartan.
In patients whose renal function may be dependent on a functioning renin-angiotensin system (eg, patients with congestive heart failure), treatment with ACE inhibitors or losartan has been associated with oliguria and/or progressive azotemia and rarely, with renal failure and/or death. A lower dose is also recommended for cirrhotic patients.
In patients with unilateral or bilateral renal artery stenosis, treatment with ACE inhibitors and losartan has been associated with an increase in BUN or serum creatinine which was reversible on discontinuation.
Angizaar-H: Due to hyperglycaemic effects of thiazide diuretics, dosage adjustments for insulin or oral hypoglycaemic agents in diabetic patients are required.
Carcinogenicity, Mutagenicity & Impairment of Fertility: Losartan was not carcinogenic when administered at maximally tolerated dosages to rats and mice for 105 and 92 weeks, respectively. Losartan potassium and its active metabolite were negative in the microbial mutagenesis and V-79 mammalian cell mutagenesis assays.
Fertility and reproductive performance were not affected in the studies with rats given oral doses of losartan up to approximately 150 mg/kg/day.
Use in pregnancy: As with other drugs that act on the renin-angiotensin system, losartan should not be administered to pregnant patients and should be discontinued as soon as pregnancy is detected.
Use in lactation: Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue losartan, taking into account the importance of the drug to the mother.
Use in children: Efficacy and safety of losartan have not been investigated in patients <18 years.
Use in the elderly: Some older individuals may be more sensitive to the effects of losartan and a lower starting dose for patients >75 years is recommended.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in